The question arises as to what kind of specific or ancillary roles cyclin D2 could play in the pathomechanism of AD, and what cD2-targeted treatments and/or therapies could be the most efficacious in the clinical management of AD and perhaps other progressive neurodegenerative disorders. The gene discussed is CCND2; the disease is Alzheimer disease.